Sorafenib in melanoma

Bibliography

• Danson S, Lorigan P. Improving outcomes in advanced malignant melanoma: update on systemic therapy. Drugs 2005;65(6):733-43
   PubMed Web of Science ®Google Scholar
• MacKie RM, Hauschild A, Eggermont AM. Epidemiology of invasive cutaneous melanoma. Ann Oncol 2009;20(Suppl 6):vi1-7
   PubMed Web of Science ®Google Scholar
• Falkson CI, Ibrahim J, Kirkwood JM, Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998;16(5):1743-51
   PubMed Web of Science ®Google Scholar
• Middleton MR, Lorigan P, Owen J, A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer 2000;82(6):1158-62
   PubMed Web of Science ®Google Scholar
• Dummer R, Panizzon R, Bloch PH, Burg G. Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology 2005;210(1):39-44
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-23
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364(26):2517-26
   PubMed Web of Science ®Google Scholar
• Bollag G, Hirth P, Tsai J, Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010;467(7315):596-9
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364(26):2507-16
   PubMed Web of Science ®Google Scholar
• Dummer R, Guggenheim M, Arnold A, Updated Swiss Guidelines for the treatment and follow up of cutaneous melanoma. Swiss Med Wkly 2011; In press
   PubMed Web of Science ®Google Scholar
• Dummer R, Hauschild A, Guggenheim M, Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v194-7
   PubMed Web of Science ®Google Scholar
• Garbe C, Eigentler TK, Keilholz U, Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011;16(1):5-24
   PubMed Web of Science ®Google Scholar
• Hutson TE. Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview. Expert Rev Anticancer Ther 2007;7(9):1193-202
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949-54
   PubMed Web of Science ®Google Scholar
• Albino AP, Le Strange R, Oliff AI, Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity? Nature 1984;308(5954):69-72
   PubMed Web of Science ®Google Scholar
• Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24(26):4340-6
   PubMed Web of Science ®Google Scholar
• Solit DB, Garraway LA, Pratilas CA, BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006;439(7074):358-62
   PubMed Web of Science ®Google Scholar
• Kefford R, Arkenau H, Brown MP, Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors [abstract 8503]. 2010 ASCO Annual Meeting. J Clin Oncol 2010;28(Suppl):15s
   PubMed Web of Science ®Google Scholar
• Poulikakos PI, Zhang C, Bollag G, RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464(7287):427-30
   PubMed Web of Science ®Google Scholar
• Heidorn SJ, Milagre C, Whittaker S, Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010;140(2):209-21
   PubMed Web of Science ®Google Scholar
• Paraiso KH, Xiang Y, Rebecca VW, PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 2011;71(7):2750-60
   PubMed Web of Science ®Google Scholar
• Dummer R, Flaherty K. Resistance patterns with tyrosie kinase inhibiors in melanoma: new insights. Curr Opin Oncol 2012; In press
   PubMed Web of Science ®Google Scholar
• Long GV, Menzies AM, Nagrial AM, Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011;29(10):1239-46
   PubMed Web of Science ®Google Scholar
• Arozarena I, Sanchez-Laorden B, Packer L, Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell 2011;19(1):45-57
   PubMed Web of Science ®Google Scholar
• Williams VL, Cohen PR, Stewart DJ. Sorafenib-induced premalignant and malignant skin lesions. Int J Dermatol 2011;50(4):396-402
   PubMed Web of Science ®Google Scholar
• Hatzivassiliou G, Song K, Yen I, RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010;464(7287):431-5
   PubMed Web of Science ®Google Scholar
• Nazarian R, Shi H, Wang Q, Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468(7326):973-7
   PubMed Web of Science ®Google Scholar
• Johannessen CM, Boehm JS, Kim SY, COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010;468(7326):968-72
   PubMed Web of Science ®Google Scholar
• Villanueva J, Vultur A, Lee JT, Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010;18(6):683-95
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64(19):7099-109
   PubMed Web of Science ®Google Scholar
• Yu C, Rahmani M, Almenara J, Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1/MEK/ERK- and AKT-dependent process. Oncogene 2004;23(7):1364-76
   PubMed Web of Science ®Google Scholar
• Panka DJ, Wang W, Atkins MB, Mier JW. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res 2006;66(3):1611-19
   PubMed Web of Science ®Google Scholar
• Rahmani M, Davis EM, Bauer C, Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem 2005;280(42):35217-27
   PubMed Web of Science ®Google Scholar
• Wan PT, Garnett MJ, Roe SM, Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116(6):855-67
   PubMed Web of Science ®Google Scholar
• Carlomagno F, Anaganti S, Guida T, BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006;98(5):326-34
   PubMed Web of Science ®Google Scholar
• Streit M, Detmar M. Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene 2003;22(20):3172-9
   PubMed Web of Science ®Google Scholar
• Claffey KP, Brown LF, del Aguila LF, Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 1996;56(1):172-81
   PubMed Web of Science ®Google Scholar
• Yu JL, Rak JW, Klement G, Kerbel RS. Vascular endothelial growth factor isoform expression as a determinant of blood vessel patterning in human melanoma xenografts. Cancer Res 2002;62(6):1838-46
   PubMed Web of Science ®Google Scholar
• Rini BI. Sorafenib. Expert Opin Pharmacother 2006;7(4):453-61
   PubMed Web of Science ®Google Scholar
• Smith RA, Barbosa J, Blum CL, Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach. Bioorg Med Chem Lett 2001;11(20):2775-8
   PubMed Web of Science ®Google Scholar
• Lowinger TB, Riedl B, Dumas J, Smith RA. Design and discovery of small molecules targeting raf-1 kinase. Curr Pharm Des 2002;8(25):2269-78
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Redlinger M, Schuchter LM, Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43-9006 alone in patients with metastatic melanoma. J Clin Oncol 2005;23(16S):3037
   Google Scholar
• Lathia C, Lettieri J, Cihon F, Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 2006;57(5):685-92
   PubMed Web of Science ®Google Scholar
• Agency EM. Sorafenib (Nexavar): summary of product characteristics (online). Available from: http://wwwemeaeuropaeu/humandocs/PDFs/EPAR7nexavar/H-690-Pi-enpdf17
   Google Scholar
• Miller AA, Murry DJ, Owzar K, Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol 2007;25(21):3055-60
   PubMed Web of Science ®Google Scholar
• Eisen T, Ahmad T, Flaherty KT, Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 2006;95(5):581-6
   PubMed Web of Science ®Google Scholar
• Pavlick A, Liebes L, Osman I, Sorafenib down regulation of the RAS/BRAF/MEK/MAPK pathway:clinical, pathologic and PET correlation. Melanoma Res 2006;16(1):S96-S7
   Google Scholar
• Ott PA, Hamilton A, Min C, A phase II trial of sorafenib in metastatic melanoma with tissue correlates. PLoS One 2010;5(12):e15588
   PubMed Web of Science ®Google Scholar
• Lev DC, Ruiz M, Mills L, Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther 2003;2(8):753-63
   PubMed Web of Science ®Google Scholar
• Eisen T, Marais R, Affolter A, Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. Br J Cancer 2011;105(3):353-9
   PubMed Web of Science ®Google Scholar
• McDermott DF, Sosman JA, Gonzalez R, Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 2008;26(13):2178-85
   PubMed Web of Science ®Google Scholar
• Lorigan P, Corrie P, Chao D, Phase II trial of sorafenib combined with dacarbazine in metastatic melanoma patients. 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24(18 Suppl 20):8012
   Web of Science ®Google Scholar
• Barysch MJ, Karpova MB, Steinert H, In vivo metabolic activity and transcriptional profiling in melanoma (MM) patients during sorafenib and dacarbazine (DTIC) treatment. ASCO Meeting Abstr 2010;28(15 Suppl):8575
   Google Scholar
• Amaravadi RK, Schuchter LM, McDermott DF, Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases. Clin Cancer Res 2009;15(24):7711-18
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Schiller J, Schuchter LM, A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res 2008;14(15):4836-42
   PubMed Web of Science ®Google Scholar
• Hauschild A, Agarwala SS, Trefzer U, Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009;27(17):2823-30
   PubMed Web of Science ®Google Scholar
• Hodi FS, Soiffer RJ, Clark J, Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol 2002;25(3):283-6
   PubMed Web of Science ®Google Scholar
• Pflugfelder A, Eigentler TK, Keim U, Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma. PLoS One 2011;6(2):e16882
   PubMed Web of Science ®Google Scholar
• Kim KB, Sosman JA, Fruehauf JP, BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 2012;30(1):34-41
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Lee SJ, Schuchter LM, Final results of E2603: A double-blind, randomized phase III trial comparing carboplatin©/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma [abstract 8511]. J Clin Oncol 2010;28(Suppl):15s
   PubMed Web of Science ®Google Scholar
• Escudier B, Lassau N, Angevin E, Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 2007;13(6):1801-9
   PubMed Web of Science ®Google Scholar
• Gollob JA, Rathmell WK, Richmond TM, Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 2007;25(22):3288-95
   PubMed Web of Science ®Google Scholar
• Ryan CW, Goldman BH, Lara PN Jr, Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 2007;25(22):3296-301
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Suciu S, Santinami M, Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008;372(9633):117-26
   PubMed Web of Science ®Google Scholar
• Egberts F, Gutzmer R, Ugurel S, Sorafenib and pegylated interferon-alpha2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. Ann Oncol 2011;22(7):1667-74
   PubMed Web of Science ®Google Scholar
• Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma (STREAM). Available from: http://www.clinicaltrial.gov/ct2/show/NCT01377025?term=sorafenib+AND+melanoma&rank=9
   Google Scholar
• Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma. Available from: http://www.clinicaltrial.gov/ct2/show/NCT00349206?term=sorafenib+AND+melanoma; National Institute of Health
   Google Scholar
• Lee HJ, Wall BA, Wangari-Talbot J, Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies. Clin Cancer Res 2011;17(22):7080-92
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34
   PubMed Web of Science ®Google Scholar
• Kane RC, Farrell AT, Saber H, Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006;12(24):7271-8
   PubMed Web of Science ®Google Scholar
• Strumberg D, Clark JW, Awada A, Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007;12(4):426-37
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Eisen T, Stadler WM, Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(16):2505-12
   PubMed Web of Science ®Google Scholar
• Arnault JP, Wechsler J, Escudier B, Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 2009;27(23):e59-61
   PubMed Web of Science ®Google Scholar
• Bennani-Lahlou M, Mateus C, Escudier B, Eruptive nevi associated with sorafenib treatment. Ann Dermatol Venereol 2008;135(10):672-4
   PubMed Web of Science ®Google Scholar
• Autier J, Escudier B, Wechsler J, Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008;144(7):886-92
   PubMed Web of Science ®Google Scholar
• Janusch M, Fischer M, Marsch W, The hand-foot syndrome–a frequent secondary manifestation in antineoplastic chemotherapy. Eur J Dermatol 2006;16(5):494-9
   PubMed Web of Science ®Google Scholar
• Yang CH, Lin WC, Chuang CK, Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008;158(3):592-6
   PubMed Web of Science ®Google Scholar
• Beldner M, Jacobson M, Burges GE, Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib. Oncologist 2007;12(10):1178-82
   PubMed Web of Science ®Google Scholar
• Porta C, Paglino C, Imarisio I, Bonomi L. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med 2007;7(4):127-34
   PubMed Web of Science ®Google Scholar
• Azad NS, Aragon-Ching JB, Dahut WL, Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 2009;15(4):1411-16
   PubMed Web of Science ®Google Scholar
• Lee JM, Sarosy GA, Annunziata CM, Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity. Br J Cancer 2010;102(3):495-9
   PubMed Web of Science ®Google Scholar
• Richly H, Henning BF, Kupsch P, Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 2006;17(5):866-73
   PubMed Web of Science ®Google Scholar
• Richly H, Kupsch P, Passage K, Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer. Int J Clin Pharmacol Ther 2004;42(11):650-1
   PubMedGoogle Scholar
• Blanchet B, Billemont B, Barete S, Toxicity of sorafenib: clinical and molecular aspects. Expert Opin Drug Saf 2010;9(2):275-87
   PubMed Web of Science ®Google Scholar
• Lin WM, Baker AC, Beroukhim R, Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res 2008;68(3):664-73
   PubMed Web of Science ®Google Scholar
• Whiteman DC, Pavan WJ, Bastian BC. The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res 2011;24(5):879-97
   PubMed Web of Science ®Google Scholar
• Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009;69(2):223-40
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27(20):3312-18
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10(1):25-34
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-90
   PubMed Web of Science ®Google Scholar